METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / CALCIUM CHANNEL BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION

The disclosure relates to a method for managing the risk of dronedarone/calcium channel blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	RADZIK DAVIDE, GAUD CHRISTINE
Format:	Patent
Sprache:	eng
Schlagworte:	CALCULATING COMPUTING COUNTING DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FORADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORYOR FORECASTING PURPOSES HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE,COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTINGPURPOSES, NOT OTHERWISE PROVIDED FOR
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The disclosure relates to a method for managing the risk of dronedarone/calcium channel blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a calcium channel blockers treatment, by performing the following steps: a-initiate calcium channel blockers treatment at a low dose; b-performing a electrocardiogram (ECG) verification of good tolerability; c-increase of calcium channel blockers dose only if results in step b) are satisfying.